title: [The treatment of chronic hepatitis C with interferon in patients infected with the human immunodeficiency virus. The Spanish Group for the Study of Viral Hepatitis in HIV+ Patients].
abstract: BACKGROUND
  Alfa-interferon (aIFN) is widely recommended for the treatment of chronic hepatitis C (CHC). Hepatitis C virus (HCV) infection is very common in injecting drug users (IDUs), which in Spain represent the large number of HIV-infected persons. Interaction between human immunodeficiency virus (HIV) and HCV in coinfected patients might accelerate the clinical course of HCV-associated liver disease. The efficacy and safety of aIFN therapy in HIV-infected patients with CHC is not well known.
  
  
  METHODS
  In a multicenter, prospective, open, non randomized and partially controlled study, we compared the efficacy and safety of aIFN therapy in 119 patients with CHC, of whom 90 were HIV-positive and 29 HIV-negative. Interferon was started at 5 mega U tiw for 3 months, followed in responders by 3 megaU tiw for additional 9 months.
  
  
  RESULTS
  One hundred seven patients completed the study. A normalization of the aminotransferase values at the end of treatment (complete response, CR) was observed in 26/80 (32.5%) HIV-positive and 10/27 (37.0%) HIV-negative individuals (p = 0.666). Relapses at 12 months of stopping aIFN were seen in 30.8% of HIV-positive subjects and 12.5% of HIV-negatives (p = 0.403). Side effects were uncommon and did not have severity; only one patient required to stop the medication. However, 3 HIV-positive subjects treated with aIFN (3.5% of them) showed an irreversible fall of CD4+ T-cells below half the baseline values.
  
  
  CONCLUSIONS
  HIV-infected patients with CHC seems to respond to aIFN with a similar rate than HIV-negatives. Moreover, the drug is similarly well tolerated in both groups of patients, although a fall of CD4+ T-cells is an unusual side effect of particular relevance observed in HIV-infected patients.
authors.affiliation: Centro de Investigaciones Clínicas, Instituto de Salud Carlos III, Madrid.
authors.forename: V
authors.initials: V
authors.lastname: Soriano
authors.forename: J
authors.initials: J
authors.lastname: García-Samaniego
authors.forename: R
authors.initials: R
authors.lastname: Bravo
authors.forename: J
authors.initials: J
authors.lastname: González
authors.forename: A
authors.initials: A
authors.lastname: Castro
authors.forename: P
authors.initials: P
authors.lastname: Martńez-Odriozola
authors.forename: M
authors.initials: M
authors.lastname: Colmenero
authors.forename: E
authors.initials: E
authors.lastname: Carballo
authors.forename: D
authors.initials: D
authors.lastname: Suárez
authors.forename: J
authors.initials: J
authors.lastname: Castilla
authors.forename: F J
authors.initials: FJ
authors.lastname: Rodriguez-Piñero
authors.forename: A
authors.initials: A
authors.lastname: Moreno
authors.forename: J
authors.initials: J
authors.lastname: del Romero
authors.forename: J
authors.initials: J
authors.lastname: Pedreira
authors.forename: J
authors.initials: J
authors.lastname: González-Lahoz
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000628:therapy*; D000328:Adult; D016009:Chi-Square Distribution; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000150:complications / Q000188:drug therapy; D015497:HIV-1 / Q000276:immunology; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011994:Recombinant Proteins; D013030:Spain; D013997:Time Factors
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins